Dapagliflozin for the treatment of chronic kidney disease

References

• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Mimura I, Tanaka T, et al. Treatment of diabetic kidney disease: current and future. Diabetes Metab J. 2021;45(1):11–26.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 2021;26(6):491–500.
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T. The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors. Int Med. 2018;57(15):2105–2114.
   PubMedGoogle Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17–27.
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type ii inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405–414.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obesity Metab. 2011;13(8):770–773.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33(11):1798–1808.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432–444.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Polidori D, Zambrowicz B, et al. Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport. Diabetes Care. 2015;38(12):2344–2353.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–519.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–526.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54(7):691–708.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care. 2010;33(10):2217–2224.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233.
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–938.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478.
   PubMed Web of Science ®Google Scholar
• JP W, Woo V, NG S, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415.
   PubMedGoogle Scholar
• Wiviott SD, Raz I, Bonaca MP, et al., Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Mcmurray JJV, Solomon SD, Inzucchi SE, et al., Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction. Circulation. 2021;143(4):298–309.
   PubMedGoogle Scholar
• Perkovic V, Jardine MJ, Neal B, et al., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15): 1436–1446.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Vart P, Jongs N, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352–2361.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215–224.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial. Nephrol Dial Transplant. 2021. DOI:https://doi.org/10.1093/ndt/gfab335.
   Google Scholar
• Wang X, Zhang S, Liu Y, et al. Targeting of sodium–glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han: sPRDrats. Kidney Int. 2013;84(5):962–968.
   PubMedGoogle Scholar
• Rodriguez D, Kapoor S, Edenhofer I, et al. Inhibition of sodium-glucosecotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease. Kidney Blood Pressure Res. 2015;40(6):638–647.
   PubMedGoogle Scholar
• Kapoor S, Rodriguez D, Riwanto M, et al. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLOS ONE. 2015;10(4):e0125603.
   PubMed Web of Science ®Google Scholar
• Leonhard WN, Song X, Kanhai AA, et al. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine. 2019;47:436–445.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al., Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Wanner C, and Green JB, et al. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dialysis Transplant. 2022;37(7):1317–1329.
   PubMed Web of Science ®Google Scholar
• Silverii GA, Monami M, Mannucci E. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2021;23(4):1052–1056.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Sjöström CD, Jongs N, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42(13):1216–1227.
   PubMed Web of Science ®Google Scholar
• Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023–1039.
   PubMed Web of Science ®Google Scholar
• Kidokoro K, Cherney DZI, Bozovic A, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140(4):303–315.
   PubMed Web of Science ®Google Scholar
• Meraz-Munoz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360. 2021;2(6):1042–1047.
   PubMedGoogle Scholar
• Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–754.
   PubMedGoogle Scholar
• FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). [cited 2022 May 7]. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin-invokana-invokamet-and
   Google Scholar
• Perlman A, Heyman SN, Matok I, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27(12):1108–1113.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Cherney D, Postmus D, et al. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101(1):174–184.
   PubMed Web of Science ®Google Scholar
• Lin DS-H, Lee J-K, Chen W-J. Clinical adverse events associated with sodium–glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab. 2021;106(7):2133–2145.
   PubMedGoogle Scholar
• Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–535.
   PubMed Web of Science ®Google Scholar
• Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021;99(4):999–1009.
   PubMedGoogle Scholar
• Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586–594.
   PubMed Web of Science ®Google Scholar
• Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755–766.
   PubMed Web of Science ®Google Scholar
• Hiddo J, Heerspink NJ L, Glenn M, et al. The effect of dapagliflozin on rate of kidney function decline in patients with CKD: a prespecified analysis from the DAPA-CKD trial; 2021. Available from: https://www.asn-online.org/education/kidneyweek/archives/KW21Abstracts.pdf
   Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617.
   PubMed Web of Science ®Google Scholar
• Nagasu H, Yano Y, Kanegae H, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the japan chronic kidney disease database. Diabetes Care. 2021;44(11):2542–2551.
   PubMedGoogle Scholar
• Li J, Neal B, Perkovic V, et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020;98(3):769–777.
   PubMedGoogle Scholar
• Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obesity Metab. 2018;20(3):479–487.
   PubMed Web of Science ®Google Scholar
• Scholtes RA, Muskiet MHA, MJB VB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440–447.
   PubMed Web of Science ®Google Scholar
• Liu L, Ni YQ, Zhan JK, et al. The role of SGLT2 inhibitors in vascular aging. Aging Dis. 2021;12(5):1323–1336.
   PubMedGoogle Scholar
• Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019;21(8):70.
   PubMed Web of Science ®Google Scholar
• Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394.
   PubMed Web of Science ®Google Scholar
• Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):1.
   PubMedGoogle Scholar
• Wan N, Rahman A, Hitomi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne). 2018;9(421). DOI:https://doi.org/10.3389/fendo.2018.00421
   Google Scholar
• Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor–induced sympathoinhibition. Jacc. 2020;5(2):169–179.
   Google Scholar
• Brown E, Wilding JPH, Barber TM, Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obesity Rev. 2019;20(6):816–828.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ö L, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031.
   PubMed Web of Science ®Google Scholar
• Yjm ODK, De LM, Dautzenberg B, et al. Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial. Diabetes Care. 2021;44(6):1334–1343.
   PubMedGoogle Scholar
• Petrykiv S, Sjöström CD, Greasley PJ, et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12(5):751–759.
   PubMedGoogle Scholar
• Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–1987.
   PubMed Web of Science ®Google Scholar
• Kolkailah AA, Wiviott SD, Raz I, et al. Effect of dapagliflozin on hematocrit in patients with type 2 diabetes at high cardiovascular risk: observations from DECLARE-TIMI 58. Diabetes Care. 2022;45(2):e27–e29.
   PubMedGoogle Scholar
• Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obesity Metab. 2013;15(9):853–862.
   PubMed Web of Science ®Google Scholar
• O’Neill J, Fasching A, Pihl L, et al. SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227–234.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Tanaka T, Nangaku M. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2020;29(4):414–422.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka T, Nangaku M. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney. Kidney360. 2020;1(9):1021–1031.
   PubMedGoogle Scholar
• Laursen JC, Søndergaard-Heinrich N, Jml DM, et al. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine. 2021;37:100895.
   PubMedGoogle Scholar
• Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016;59(12):2546–2551.
   PubMedGoogle Scholar
• Nair AV, Hocher B, Verkaart S, et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Nat Acad Sci. 2012;109(28):11324–11329.
   PubMed Web of Science ®Google Scholar
• Ray EC, Boyd-Shiwarski CR, Liu P, et al. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients. Kidney Med. 2020;2(3):359–364
   PubMedGoogle Scholar
• Ng HY, Kuo WH, Tain YL, et al. Effect of dapagliflozin and magnesium supplementation on renal magnesium handling and magnesium homeostasis in metabolic syndrome. Nutrients. 2021;13(11):4088.
   PubMedGoogle Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462.
   PubMed Web of Science ®Google Scholar
• Suijk DLS, MJB VB, EJM VB, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663–671.
   PubMedGoogle Scholar
• Musso G, Saba F, Cassader M, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020;371(m4147). DOI:https://doi.org/10.1136/bmj.m4147
   Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195.
   PubMed Web of Science ®Google Scholar
• Helal I, Fick-Brosnahan GM, Reed-Gitomer B, et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8(5):293–300.
   PubMed Web of Science ®Google Scholar
• Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99(3):750–762.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Sugiura Y, Saito H, et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018;94(5):912–925.
   PubMed Web of Science ®Google Scholar
• Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6(11):667–678.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013;9(4):211–222.
   PubMed Web of Science ®Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92(2):306–312.
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(5):331–338.
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Tanaka T, Saito T, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2020;97(5):934–950.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka S, Tanaka T, et al. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol. 2020;31(3):560–577.
   PubMed Web of Science ®Google Scholar
• Saito H, Tanaka T, Sugahara M, et al. Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. Lab Invest. 2019;99(8):1217–1232.
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T, Ishii T, et al. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. Kidney Int. 2020;97(4):687–701.
   PubMed Web of Science ®Google Scholar
• Volpe CMO, Villar-Delfino PH, Pmf DA, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):2.
   PubMedGoogle Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820.
   PubMed Web of Science ®Google Scholar
• Maruno S, Tanaka T, Nangaku M. Exploring molecular targets in diabetic kidney disease. Kidney Res Clin Pract. 2022. DOI:https://doi.org/10.23876/j.krcp.21.251
   Google Scholar
• Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-Receptor axis. Hormone Metab Res. 2015;47(9):686–692.
   PubMed Web of Science ®Google Scholar
• Rojas-Morales P, Pedraza-Chaverri J, Tapia E. Ketone bodies for kidney injury and disease. Adv Redox Res. 2021;2(100009):100009
   Google Scholar
• Tajima T, Yoshifuji A, Matsui A, et al. β-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects. Kidney Int. 2019;95(5):1120–1137.
   PubMed Web of Science ®Google Scholar
• Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32(3):404–419.e406.
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen B, Gong AY, et al. The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults. Kidney Int. 2021;100(5):1037–1053.
   PubMedGoogle Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–1122.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44(6):457–464.
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obesity Metab. 2018;20(8):1988–1993.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154–1166.
   PubMed Web of Science ®Google Scholar
• Kim SR, Lee S-G, and Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(2):356–363.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Vart P, Jongs N, et al. Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes Obes Metab. 2022;24(5):827–837.
   PubMedGoogle Scholar
• Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–274.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Vart P, et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021;44(8):1894–1897.
   PubMedGoogle Scholar
• Alsahli M, Gerich J. Hypoglycemia in patients with diabetes and renal disease. J Clin Med. 2015;4(5):948–964.
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340(jan08 1):b5444–b5444.
   PubMedGoogle Scholar
• Thomson SC, Vallon V. Renal effects of sodium-glucose co-transporter inhibitors. Am J Med. 2019;132(10):S30–S38.e34.
   Google Scholar
• Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204–221.
   PubMed Web of Science ®Google Scholar
• Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obesity Metab. 2017;19(3):348–355.
   PubMed Web of Science ®Google Scholar
• Puckrin R, Saltiel MP, Reynier P, et al. inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–514.
   PubMed Web of Science ®Google Scholar
• Dave CV, Schneeweiss S, Kim D, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–256.
   PubMed Web of Science ®Google Scholar
• Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother. 2021;55(4):543–548.
   PubMedGoogle Scholar
• Milder TY, Stocker SL, Day RO, et al. Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf. 2020;43(12):1211–1221.
   PubMed Web of Science ®Google Scholar
• FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious#:~:text=FDA%20has%20added%20warnings%20about,and%20serious%20urinary%20tract%20infections.
   Google Scholar
• Goldenberg RM. Sodium-glucose cotransporter-2 inhibitors increase risk of diabetic ketoacidosis in adults with type 2 diabetes: should we be concerned in people without diabetes? Can J Diabetes. 2022;46(2):109.
   PubMedGoogle Scholar
• Liu J, Li L, Li S, et al. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials. Diabetes Obesity Metab. 2020;22(9):1619–1627.
   PubMed Web of Science ®Google Scholar
• Blau JE, Tella SH, Taylor SI, et al. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017;33(8):e2924.
   Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol. 2021;16(8):1284–1291.
   PubMedGoogle Scholar
• Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Provenzano M, Jongs N, Vart P, et al. The kidney protective effects of the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436–443.
   PubMedGoogle Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• Rossing P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36–45.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145(19):1460–1470.
   PubMed Web of Science ®Google Scholar
• Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study. Diabetes Care. 2020;43(2):468–475.
   PubMed Web of Science ®Google Scholar
• Murata Y, Kadoya Y, Yamada S, et al. Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors. Diabetol int. 2018;9(2):136–142.
   PubMedGoogle Scholar
• Wang T, Feng X, Zhou J, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep. 2016;6(1):38937.
   PubMedGoogle Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14(6):795–800.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018;25(6):467–476.
   PubMed Web of Science ®Google Scholar
• Yamakage H, Tanaka M, Inoue T, et al. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial. J Diabetes Investig. 2020;11(3):653–661.
   PubMedGoogle Scholar
• Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) study. J Diabetes Investig. 2019;10(1):108–117.
   PubMed Web of Science ®Google Scholar
• Kamei S, Iwamoto M, Kameyama M, et al. Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus. J Diabetes Res. 2018;1-6:2018.
   Google Scholar
• Yasuda M, Iizuka K, Kato T, et al. Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report. J Diabetes Investig. 2020;11(3):745–747.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Chiu N, Bhatt DL. Generalizability of DAPA-CKD to the United States. Circulation Cardiovasc Qual Outcomes. 2021;14(7).
   PubMedGoogle Scholar
• Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1).
   PubMedGoogle Scholar
• Ganz M, Ustyugova A, Sawalhi-Leckenby N, et al. Utilization of glucose-lowering drugs in patients with T2dm and established CVD in us: a descriptive study using Optum clinformatics data. J Am Coll Cardiol. 2020;75(11):2017.
   Google Scholar
• Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the Proper Use of SGLT2 Inhibitors. J Diabetes Investig. 2020;11(1):257–261.
   PubMed Web of Science ®Google Scholar
• Khoo CM, Deerochanawong C, Chan SP, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations. Diabetes Obes Metab. 2021;23(2):299–317.
   PubMedGoogle Scholar
• KDIGO, De Boer IH, Caramori ML, Chan JCN, et al. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98(4):S1–S115.
   PubMedGoogle Scholar
• UKKA clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. Available from: https://ukkidney.org/health-professionals/guidelines/guidelines-commentaries.
   Google Scholar
• Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29(2):190–198.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295(42):14379–14390.
   PubMed Web of Science ®Google Scholar
• Marton A, Kaneko T, Kovalik JP, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2021;17(1):65–77.
   PubMed Web of Science ®Google Scholar
• Pollock C, Neuen BL, Cotransporter S-G. 2 Inhibition: rationale and mechanisms for kidney and cardiovascular protection in people with and without diabetes. Adv Chronic Kidney Dis. 2021;28(4):298–308.
   PubMedGoogle Scholar
• Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33(4):732–739.
   PubMed Web of Science ®Google Scholar
• Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83(1):503–528.
   PubMedGoogle Scholar
• American Diabetes Association Professional Practice C, Draznin B, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 2022;45(Suppl 1):S175–S184.
   PubMedGoogle Scholar